Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease
| Autor: | Roberto F E Pedretti, Ferdinando Varbella, Domenico Gabrielli, Alessio La Manna, Emilia Chiuini, Federico Nardi, Giovanni Battista Zito, Pompilio Faggiano, Alfredo Marchese, Fortunato Scotto di Uccio, Carmine Riccio, Marco Ambrosetti, Aldo P. Maggioni, Massimo Piredda, F. Massari, Roberta Rossini, Maurizio Giuseppe Abrignani, Nadia Aspromonte, Roberto Caporale, Stefano Urbinati, Giancarlo Casolo, Gian Francesco Mureddu, Andrea Di Lenarda, Leonardo De Luca, Michele Massimo Gulizia, Enrico Pusineri, Antonio Vittorio Panno, Giovanna Geraci, Furio Colivicchi, Giuseppe Musumeci, Gabriella Barile |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome animal structures medicine.medical_treatment 030204 cardiovascular system & hematology Coronary artery disease Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine cardiovascular diseases 030212 general & internal medicine Long-term dual antiplatelet therapy Aspirin business.industry Percutaneous coronary intervention medicine.disease Thrombosis Prior myocardial infarction Regimen Dual antiplatelet therapy Conventional PCI Cardiology Cardiology and Cardiovascular Medicine business Kidney disease medicine.drug |
| Zdroj: | European Heart Journal Supplements : Journal of the European Society of Cardiology |
| ISSN: | 1554-2815 1520-765X |
| DOI: | 10.1093/eurheartj/suy019 |
| Popis: | Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of pharmacologic management of patients with acute coronary syndrome (ACS) and/or those receiving coronary stents. Long-term (>1 year) DAPT may further reduce the risk of stent thrombosis after a percutaneous coronary intervention (PCI) and may decrease the occurrence of non-stent-related ischaemic events in patients with ACS. Nevertheless, compared with aspirin alone, extended use of aspirin plus a P2Y12 receptor inhibitor may increase the risk of bleeding events that have been strongly linked to adverse outcomes including recurrent ischaemia, repeat hospitalisation and death. In the past years, multiple randomised trials have been published comparing the duration of DAPT after PCI and in ACS patients, investigating either a shorter or prolonged DAPT regimen. Although the current European Society of Cardiology guidelines provide a backup to individualised treatment, it appears to be difficult to identify the ideal patient profile which could safely reduce or prolong the DAPT duration in daily clinical practice. The aim of this consensus document is to review contemporary literature on optimal DAPT duration, and to guide clinicians in tailoring antiplatelet strategies in patients undergoing PCI or presenting with ACS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|